The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Overcoming on-target, off-tumor toxicity in AML: current challenges and potential solutions
Eunice Wang, MD, Roswell Park Cancer Center, Buffalo, NY, discusses the problems with current immunotherapies for acute myeloid leukemia (AML), highlighting how the lack of a precise target means CAR-T therapies might affect both healthy hematopoietic and malignant cells. Dr Wang suggests potential solutions to overcome this. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
